Phase 3
N=104
The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Disorder of Urinary Stent
Bottom Line
View on ClinicalTrials.gov: NCT01530243 ↗Enrolled (actual)
104
Serious AEs
13.8%
Results posted
Mar 2015
Primary outcome: Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Placebo (Drug); Terazosine (Drug); Tolterodine (Drug); Tolterodine + Terazosin (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Urmia University of Medical Sciences
- Primary completion
- Aug 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lower Urinary Tract Symptoms (LUTS) |
11.12; 4.39; 7.21; 5.58 | — |
| SECONDARY Quality of Life |
3.37; 2; 2.30; 0.95 | — |
Summary
The aim of the investigators study is to evaluate whether alpha-blockers such as terazosin and anti-cholinergics such as tolterodine can be relieve the DJ-stent related symptoms.
Eligibility Criteria
Inclusion Criteria
If a patient does not meet any exclusion criteria and to be undergone double-J stent indwelling.
Exclusion Criteria
- Prior history of pelvic surgery
- Prior history of Transurethral Resection of the either Prostate or Bladder Tumor
- Benign prostate hyperplasia
- Recent or recurrent urinary tract infection
- Chronic medication with beta-blockers or Anti-cholinergic
- Pregnancy
- Prostatitis
- Prostate cancer
- Bilateral ureteroscopy or ureteral stenting
- Age 55
- Stone size > 20 mm
- Diabetes
- Bladder Outlet Obstruction
Data sourced from ClinicalTrials.gov (NCT01530243). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.